| Factor Information | |
|---|---|
| Data ID | 411 |
| Factor | NYHA class III/IV |
| Description | Soluble suppression of tumorogenicity 2 (sST2) has been shown to be of prognostic value in patients with chronic and acute left heart failure. |
| Biomarker | NA |
| Classification | A6 (clinical factor - other) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | to assess the predictive value of sST2 levels in adult patients with complex congenital heart disease (CHD). |
| p Value | <0.001 |
| Conclusion | In patients with complex CHD, sST2 may have additive value to natriuretic peptides for the prediction of all-cause mortality |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 448 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | CRHD/other/SRV/EIS/complex CHD |
| Reference | |
|---|---|
| PMID | 30118521 |
| Year | 2018 |
| Title | Predictive value of soluble ST2 in adolescent and adult patients with complex congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | consecutive patients with complex CHD | |
| Source | Blood | |
| Region | Homburg/Saar,Germany | |
| Method | In all participants, venous blood samples were drawn into standard sampling tubes after echocardiography. | |
| Race | Europe | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | patients with MACE(Treatment) | patients without MACE(Control) |
| Number | 17 | 152 |
| Age | 27.9 ± 13.9 years | 28.3 ± 11.8 years |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 2.4 ± 0.8 | 1.4 ± 0.6 |
